These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 1934864)

  • 1. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities.
    Kalow W; Tang BK
    Clin Pharmacol Ther; 1991 Nov; 50(5 Pt 1):508-19. PubMed ID: 1934864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Determination of caffeine metabolite for the evaluation of N-acetyltransferase, CYP1A2 and xanthine oxidase activities].
    Lu JF; Yi T; Cao XM; Zhuo HT; Ling SS
    Yao Xue Xue Bao; 1997 Nov; 32(11):813-8. PubMed ID: 11596199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping.
    Kashuba AD; Bertino JS; Kearns GL; Leeder JS; James AW; Gotschall R; Nafziger AN
    Clin Pharmacol Ther; 1998 May; 63(5):540-51. PubMed ID: 9630827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans.
    Rasmussen BB; Brøsen K
    Ther Drug Monit; 1996 Jun; 18(3):254-62. PubMed ID: 8738764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caffeine metabolism in cystic fibrosis: enhanced xanthine oxidase activity.
    Hamelin BA; Xu K; Vallé F; Manseau L; Richer M; LeBel M
    Clin Pharmacol Ther; 1994 Nov; 56(5):521-9. PubMed ID: 7955816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine.
    Vistisen K; Poulsen HE; Loft S
    Carcinogenesis; 1992 Sep; 13(9):1561-8. PubMed ID: 1394840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities.
    Relling MV; Lin JS; Ayers GD; Evans WE
    Clin Pharmacol Ther; 1992 Dec; 52(6):643-58. PubMed ID: 1458773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios.
    Begas E; Kouvaras E; Tsakalof A; Papakosta S; Asprodini EK
    Biomed Chromatogr; 2007 Feb; 21(2):190-200. PubMed ID: 17221922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism.
    Chung WG; Kang JH; Park CS; Cho MH; Cha YN
    Clin Pharmacol Ther; 2000 Mar; 67(3):258-66. PubMed ID: 10741629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers.
    Chen Y; Xiao P; Ou-Yang DS; Fan L; Guo D; Wang YN; Han Y; Tu JH; Zhou G; Huang YF; Zhou HH
    Clin Exp Pharmacol Physiol; 2009 Aug; 36(8):828-33. PubMed ID: 19215233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caffeine metabolism before and after liver transplantation.
    Bechtel YC; Lelouët H; Hrusovsky S; Brientini MP; Mantion G; Paintaud G; Miguet JP; Bechtel PR
    Int J Clin Pharmacol Ther; 2001 Feb; 39(2):53-60. PubMed ID: 11270802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
    Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
    Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females.
    Wenk M; Todesco L; Krähenbühl S
    Br J Clin Pharmacol; 2004 Apr; 57(4):495-9. PubMed ID: 15025748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of effect of terbinafine on the activity of CYP1A2, NAT-2, and xanthine oxidase.
    Trépanier EF; Nafziger AN; Kearns GL; Kashuba AD; Amsden GW
    J Clin Pharmacol; 1998 May; 38(5):424-8. PubMed ID: 9602954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test.
    Saruwatari J; Nakagawa K; Shindo J; Tajiri T; Fujieda M; Yamazaki H; Kamataki T; Ishizaki T
    Clin Pharmacol Ther; 2002 Aug; 72(2):200-8. PubMed ID: 12189367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities.
    Hakooz NM
    Curr Drug Metab; 2009 May; 10(4):329-38. PubMed ID: 19519341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome P450 IA2 activity in man measured by caffeine metabolism: effect of smoking, broccoli and exercise.
    Vistisen K; Loft S; Poulsen HE
    Adv Exp Med Biol; 1991; 283():407-11. PubMed ID: 2069014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans.
    Tsutsumi K; Kotegawa T; Matsuki S; Tanaka Y; Ishii Y; Kodama Y; Kuranari M; Miyakawa I; Nakano S
    Clin Pharmacol Ther; 2001 Aug; 70(2):121-5. PubMed ID: 11503005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of effect of growth hormone replacement therapy on CYP1A2 and xanthine oxidase activities in growth hormone-deficient children.
    Mayayo-Sinués E; Fanlo A; Sinués B; Mayayo E; Labarta JI; García de Jalón A; Ferrández-Longás A
    Eur J Clin Pharmacol; 2006 Feb; 62(2):123-7. PubMed ID: 16408225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The in-vivo effect of bakumondo-to (TJ-29), a traditional Japanese medicine used for treatment of chronic airway disease, on cytochrome P450 1A2, xanthine oxidase and N-acetyltransferase 2 activity in man.
    Saruwatari J; Hisaeda S; Higa Y; Tomiyasu Y; Nakagawa K; Ishizaki T
    J Pharm Pharmacol; 2004 Sep; 56(9):1171-7. PubMed ID: 15324486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.